Ligand Pharmaceuticals Incorporated (LGND) reported a significant increase in total revenue and income for the fiscal year ended December 31, 2025, reaching $268.1 million, a 60% increase compared to $167.1 million in 2024. This growth was primarily driven by a $52.2 million increase in royalties and a $39.4 million increase in contract revenue and income. Royalty revenue was bolstered by income from the Qarziba financial royalty asset acquired in the third quarter of 2024, as well as increased sales of Filspari, Ohtuvayre, and Capvaxive. Captisol sales also contributed to the revenue increase, rising by $9.3 million to $40.2 million due to the timing of customer orders.
The company's operating costs and expenses totaled $227.1 million in 2025, a 20% increase from $189.7 million in 2024. This rise was primarily due to a $59.8 million increase in research and development expenses, largely attributed to R&D funding arrangements related to the Castle Creek and Orchestra transactions. General and administrative expenses also increased by $13.8 million, mainly due to transaction costs. However, financial royalty asset impairment decreased by $24.4 million, and fair value adjustments to partner program derivatives were not recognized in 2025 due to the adoption of ASU 2025-07.
Ligand's net income from continuing operations for 2025 was $124.5 million, a substantial increase compared to a net loss of $4.0 million in 2024. This improvement was significantly influenced by a $92.8 million increase in non-operating income, primarily due to a $90.7 million gain from changes in the fair value of equity method investments and other investments, particularly related to the Pelthos Transaction. The company's effective tax rate for 2025 was 22%.
Key strategic developments in 2025 included royalty financing agreements with Castle Creek Biosciences and Orchestra BioMed Holdings, as well as the Pelthos Transaction, which involved the merger of Ligand's subsidiary, LNHC, with Channel Therapeutics. These transactions are expected to contribute to future revenue streams. As of December 31, 2025, Ligand had $733.5 million in cash, cash equivalents, and short-term investments. The company's management believes that its existing funds, cash generated from operations, and access to financing are adequate to meet its operational and strategic needs.
About LIGAND PHARMACEUTICALS INC
Ligand Pharmaceuticals is a biopharmaceutical company specializing in supporting drug development through licensing, licensing technology, and royalty rights. It focuses on late-stage assets, infrastructure-light platform technologies like Captisol and NITRICIL, and partnerships with leading pharma firms. Revenue streams include royalties, product sales, and milestone payments, with a diversified portfolio aimed at high-margin, low-infrastructure operations in global markets.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.